VXRT inventory forecast 2025 refers back to the predicted efficiency of the inventory of Vaxart, Inc. (VXRT) within the yr 2025. Inventory forecasts try to predict the longer term value of a inventory primarily based on varied elements similar to the corporate’s monetary efficiency, business tendencies, and general financial circumstances.
VXRT is a clinical-stage biotechnology firm targeted on creating oral vaccines for infectious illnesses. The corporate’s lead product candidate is VXA-CoV2-1, an oral vaccine for COVID-19. Vaxart has additionally developed oral vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV).
